Safety of Mepolizumab for severe eosinophilic refractory asthma in a single-center cohort including a patient with echinococcus hepatic cyst and a patient with lung cancer . A single center one year follow up.
C. Barbetta (Pordenone, Italy), M. Conte (Pordenone, Italy), F. Zampieri (Pordenone, Italy), C. Rinaldo (Pordenone, Italy), P. Peditto (Pordenone, Italy), M. Tamburrini (Pordenone, Italy), U. Zuccon (Pordenone, Italy), A. Scarda (Pordenone, Italy), C. Baghiris (Pordenone, Italy), F. Buzzulini (Pordenone, Italy), D. Villalta (Pordenone, Italy), F. Mazza (Pordenone, Italy)
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Barbetta (Pordenone, Italy), M. Conte (Pordenone, Italy), F. Zampieri (Pordenone, Italy), C. Rinaldo (Pordenone, Italy), P. Peditto (Pordenone, Italy), M. Tamburrini (Pordenone, Italy), U. Zuccon (Pordenone, Italy), A. Scarda (Pordenone, Italy), C. Baghiris (Pordenone, Italy), F. Buzzulini (Pordenone, Italy), D. Villalta (Pordenone, Italy), F. Mazza (Pordenone, Italy). Safety of Mepolizumab for severe eosinophilic refractory asthma in a single-center cohort including a patient with echinococcus hepatic cyst and a patient with lung cancer . A single center one year follow up.. 2519
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: